HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

M Untch Selected Research

human ERBB2 protein

4/2024Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE).
1/2022Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer.
1/2021Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE.
3/2013RNA-based determination of ESR1 and HER2 expression and response to neoadjuvant chemotherapy.
6/2008Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


M Untch Research Topics

Disease

61Breast Neoplasms (Breast Cancer)
04/2024 - 01/2000
37Neoplasms (Cancer)
01/2021 - 01/2000
11Triple Negative Breast Neoplasms
04/2024 - 12/2013
7Neoplasm Metastasis (Metastasis)
03/2016 - 01/2000
3Residual Neoplasm
02/2024 - 06/2001
3Thrombocytopenia (Thrombopenia)
01/2021 - 02/2011
2Diarrhea
11/2016 - 02/2011
2Disease Progression
04/2015 - 06/2001
2Sarcoma (Soft Tissue Sarcoma)
02/2015 - 04/2006
2Carcinoma (Carcinomatosis)
03/2014 - 06/2001
2Cardiotoxicity
05/2004 - 09/2000
2Ovarian Neoplasms (Ovarian Cancer)
06/2001 - 05/2000
1Second Primary Neoplasms (Neoplasms, Second)
01/2022
1Peripheral Nervous System Diseases (PNS Diseases)
01/2021
1Hemorrhage
01/2021
1Pathologic Complete Response
01/2017
1Febrile Neutropenia
11/2016
1Dizziness (Lightheadedness)
11/2016
1Myoma
02/2015
1Leiomyoma (Uterine Fibroids)
02/2015
1Hiatal Hernia
08/2013
1Airway Obstruction (Choking)
08/2013
1Inflammatory Breast Neoplasms
08/2012
1Infections
02/2011
1Leukopenia
02/2011
1Hyperlipidemias (Hyperlipidemia)
02/2011
1Edema (Dropsy)
02/2011
1Mucositis
02/2011
1Cardiovascular Diseases (Cardiovascular Disease)
02/2011
1Hypertension (High Blood Pressure)
02/2011

Drug/Important Bio-Agent (IBA)

19Trastuzumab (Herceptin)FDA Link
01/2021 - 09/2000
18Epirubicin (Ellence)FDA LinkGeneric
11/2022 - 01/2000
15Cyclophosphamide (Cytoxan)FDA LinkGeneric
11/2022 - 05/2000
12taxaneIBA
07/2022 - 09/2007
11AnthracyclinesIBA
07/2022 - 12/2004
9Paclitaxel (Taxol)FDA LinkGeneric
04/2024 - 05/2000
7Hormones (Hormone)IBA
01/2021 - 04/2002
6Biomarkers (Surrogate Marker)IBA
07/2022 - 04/2002
6Plasminogen Activator Inhibitor 1IBA
05/2013 - 01/2000
6Urokinase-Type Plasminogen Activator (Urokinase)FDA Link
05/2013 - 01/2000
5human ERBB2 proteinIBA
04/2024 - 06/2008
5Lapatinib (GW572016)FDA Link
01/2019 - 02/2011
5AntibodiesIBA
09/2007 - 01/2001
4Carboplatin (JM8)FDA LinkGeneric
01/2022 - 05/2000
4Proteins (Proteins, Gene)FDA Link
01/2015 - 09/2000
4Docetaxel (Taxotere)FDA Link
12/2014 - 02/2011
4Fluorouracil (Carac)FDA LinkGeneric
09/2007 - 09/2000
4Plasminogen InactivatorsIBA
08/2001 - 01/2000
3Immune Checkpoint InhibitorsIBA
11/2022 - 01/2019
3durvalumabIBA
11/2022 - 01/2019
3Bevacizumab (Avastin)FDA Link
12/2014 - 02/2011
3Methotrexate (Mexate)FDA LinkGeneric
09/2001 - 09/2000
3Drug CombinationsIBA
09/2001 - 05/2000
2130-nm albumin-bound paclitaxelIBA
11/2022 - 01/2017
2ParaffinIBA
12/2018 - 01/2001
2Diphosphonates (Bisphosphonates)IBA
03/2016 - 01/2016
2Zoledronic Acid (Zometa)FDA Link
03/2016 - 01/2016
2EverolimusFDA Link
12/2014 - 02/2011
2Plasminogen Activators (Plasminogen Activator)IBA
05/2013 - 04/2006
2Darbepoetin alfa (Aranesp)FDA Link
09/2011 - 09/2011
2Vinorelbine (Navelbine)FDA LinkGeneric
10/2006 - 06/2001
2Tissue ExtractsIBA
04/2006 - 08/2001
2Adenosine Triphosphate (ATP)IBA
06/2001 - 05/2000
1cabazitaxelFDA Link
04/2024
1Phenobarbital (Luminal)FDA Link
04/2024
1pembrolizumabIBA
02/2024
1veliparibIBA
01/2022
1Immunoconjugates (Immunoconjugate)IBA
01/2022
1trastuzumab deruxtecanIBA
01/2022
1Ado-Trastuzumab EmtansineIBA
01/2021
1PlatinumIBA
01/2021
1DNA (Deoxyribonucleic Acid)IBA
01/2021
1olaparibIBA
01/2021
1MutagensIBA
01/2021
1Indicators and Reagents (Reagents)IBA
01/2021
1Formaldehyde (Formol)FDA Link
12/2018
1Estrogen ReceptorsIBA
12/2018
1pertuzumabIBA
01/2017
1SolventsIBA
01/2017
1CreatinineIBA
11/2016
1Clodronic Acid (Clodronate)IBA
03/2016
1N,N'-bis(4-azidobenzoyl)cystineIBA
02/2016
1Biosimilar PharmaceuticalsIBA
04/2015
1HematinicsIBA
04/2015
1Cysteine (L-Cysteine)FDA Link
01/2015
1Capecitabine (Xeloda)FDA Link
01/2014
1Messenger RNA (mRNA)IBA
03/2013
1Growth Factor ReceptorsIBA
02/2011
1bis(beta-carboxyethyl)tin dichlorideIBA
09/2007
1Antineoplastic Agents (Antineoplastics)IBA
05/2007

Therapy/Procedure

36Drug Therapy (Chemotherapy)
02/2024 - 01/2000
26Therapeutics
01/2021 - 01/2000
22Neoadjuvant Therapy
04/2024 - 06/2001
3Adjuvant Chemotherapy
01/2019 - 01/2000
3Hysterectomy
02/2015 - 04/2006
2Cesarean Section (Caesarean Section)
03/2014 - 06/2004
1Duration of Therapy
11/2022
1Morcellation
02/2015
1Operative Surgical Procedures
02/2015
1Ex utero Intrapartum Treatment Procedures
08/2013